{"nctId":"NCT03856164","briefTitle":"Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery","startDateStruct":{"date":"2019-06-17","type":"ACTUAL"},"conditions":["Post Partum Hemorrhage","Fibrinolysis; Hemorrhage","Blood Loss"],"count":110,"armGroups":[{"label":"Tranexamic acid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tranexamic Acid"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tranexamic Acid","otherNames":["Cyklokapron"]},{"name":"Placebo","otherNames":["Normal Saline"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Intrauterine pregnancy\n2. Age ≥ 18\n3. Gestation age ≥ 37 weeks 0 days\n4. Scheduled cesarean delivery\n5. Second or third cesarean delivery\n6. Singleton pregnancy\n\nExclusion Criteria:\n\n1. First cesarean delivery\n2. Four or more cesarean deliveries\n3. Intrauterine fetal death\n4. Fetal anomalies\n5. Documented coagulopathy (Elevated Prothrombin Time (PT), Elevated Partial Thromboplastin Time (PTT), Elevated International Normalized Ratio (INR))\n6. Thrombocytopenia (Platelet count \\< 100k)\n7. Internal bleeding, external bleeding, easy bruising\n8. History of thrombotic event\n9. Hypertension\n10. Diagnosis of renal insufficiency (Creatinine\\> 1 mg/dL)\n11. Insulin-treated diabetes\n12. Suspected morbidly adherent placenta\n13. Placenta previa\n14. Multiple Gestations\n15. BMI ≥ 50\n16. Hematocrit ≤ 25\n17. Blood transfusion within 24 hours prior to cesarean delivery\n18. History of abnormal bleeding or blood disorder\n19. Planned general anesthesia","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Blood Volume Loss","description":"Total blood volume loss will be calculated in milliliters.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2274","spread":"469"},{"groupId":"OG001","value":"2407","spread":"388"}]}]}]},{"type":"SECONDARY","title":"D-Dimer (µg/mL)","description":"Measured from blood sample collection.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"1.5"},{"groupId":"OG001","value":"4.0","spread":"5.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.3"},{"groupId":"OG001","value":"3.8","spread":"4.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.2"},{"groupId":"OG001","value":"4.3","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Fibrinogen (mg/dL)","description":"Measured from blood sample collection.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"563.5","spread":"83.9"},{"groupId":"OG001","value":"550.7","spread":"68.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"499.6","spread":"77"},{"groupId":"OG001","value":"484.9","spread":"82.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"527.4","spread":"69.8"},{"groupId":"OG001","value":"525.4","spread":"86.1"}]}]}]},{"type":"SECONDARY","title":"Tissue Plasminogen Activator Antigen (ng/mL)","description":"Measured from blood sample collection.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"3.6"},{"groupId":"OG001","value":"8.2","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"3.7"},{"groupId":"OG001","value":"9.6","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"3.7"},{"groupId":"OG001","value":"7.4","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Plasminogen Activator Inhibitor-Type-1 (Units/mL)","description":"Measured from blood sample collection.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":"34.7"},{"groupId":"OG001","value":"61.7","spread":"33.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","spread":"32.3"},{"groupId":"OG001","value":"63.3","spread":"31.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":"26.7"},{"groupId":"OG001","value":"22.1","spread":"28.5"}]}]}]},{"type":"SECONDARY","title":"Rotational Thromboelastometry INTEM and EXTEM Clotting Time","description":"Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149.7","spread":"14.4"},{"groupId":"OG001","value":"150.5","spread":"14.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137.4","spread":"18.3"},{"groupId":"OG001","value":"140.7","spread":"29.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145.1","spread":"16.3"},{"groupId":"OG001","value":"141.2","spread":"16.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0","spread":"5.1"},{"groupId":"OG001","value":"56.1","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.9","spread":"6.3"},{"groupId":"OG001","value":"56.3","spread":"8.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":"5.3"},{"groupId":"OG001","value":"50.2","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"Rotational Thromboelastometry INTEM, EXTEM, FIBTEM Maximum Clot Firmness","description":"Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.3","spread":"3.3"},{"groupId":"OG001","value":"69.4","spread":"3.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.9","spread":"3.2"},{"groupId":"OG001","value":"68.4","spread":"5.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":"3.1"},{"groupId":"OG001","value":"68.8","spread":"3.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":"3.1"},{"groupId":"OG001","value":"71.2","spread":"3.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.8","spread":"3.1"},{"groupId":"OG001","value":"69.6","spread":"5.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.5","spread":"2.8"},{"groupId":"OG001","value":"70.4","spread":"4.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":"3.8"},{"groupId":"OG001","value":"23.9","spread":"4.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":"4.1"},{"groupId":"OG001","value":"22.0","spread":"4.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":"4.7"},{"groupId":"OG001","value":"25.0","spread":"5.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":55},"commonTop":[]}}}